🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Verastem Inc (0LOV)

London
Currency in USD
3.93
+3.93(+0.00%)
Closed
0LOV Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
3.753.98
52 wk Range
2.1413.94
Prev. Close
-
Open
3.93
Day's Range
3.75-3.98
52 wk Range
2.14-13.94
Volume
3,020
Average Volume (3m)
5,077
1-Year Change
-46.71%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
0LOV Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
11.88
Upside
+204.49%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Verastem Inc Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen’s KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Compare 0LOV to Peers and Sector

Metrics to compare
0LOV
Peers
Sector
Relationship
P/E Ratio
−1.8x−3.9x−0.6x
PEG Ratio
−0.070.000.00
Price/Book
8.4x3.4x2.6x
Price / LTM Sales
15.8x9.4x3.2x
Upside (Analyst Target)
-116.8%48.6%
Fair Value Upside
Unlock11.0%7.0%Unlock

People Also Watch

0.333
MRNS
+1.43%
1.7400
SGMO
-7.45%
1.7700
OTRK
-4.32%

FAQ

What Is the Verastem (0LOV) Stock Price Today?

The Verastem stock price today is 3.93

What Stock Exchange Does Verastem Trade On?

Verastem is listed and trades on the London stock exchange.

What Is the Stock Symbol for Verastem?

The stock symbol for Verastem is "0LOV."

What Is the Verastem Market Cap?

As of today, Verastem market cap is 156.75M.

What is Verastem Earnings Per Share?

The Verastem EPS is -3.33.

From a Technical Analysis Perspective, Is 0LOV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.